Supernus Pharmaceuticals

Supernus Pharmaceuticals is a pharmaceutical company focused on developing and marketing products for the treatment of central nervous system (CNS) disorders. The company offers products for epilepsy treatment, including extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). In psychiatry, the company is developing multiple product candidates for treating impulsive aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatric product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine). Currently, SPN-810 under development by the company is indicated for IA in patients with ADHD, while SPN-812 under development is intended for ADHD treatment. The company is also developing SPN-809 (viloxazine) for depression treatment. Supernus Pharmaceuticals markets its products in the United States through its specialized sales team and collaborates with other pharmaceutical companies to license its products outside the U.S.